Nicolas ETIQUE

Dr. Nicolas ETIQUE

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2011 in Oncogene
Verified
Journal Article
Open access
EBE Buache
E Buache
NENicolas ETIQUE
Nicolas ETIQUE
FAFabien Alpy
Fabien Alpy
ISI Stoll
I Stoll
MMM Muckensturm
M Muckensturm
MRM C Rio
M C Rio
Although trefoil factor 1 (TFF1; previously named pS2) is abnormally expressed in about 50% of human breast tumors, its physiopathological role in this disease has been poorly studied. Moreover, controversial data have been reported. TFF1 function in the mammary gland therefore needs to be clarified. In this study, using retroviral vectors, we performed TFF1 gain- or loss-of-function experiments in four human mammary epithelial cell lines: normal immortalized TFF1-negative MCF10A, malignant TFF1-negative MDA-MB-231 and malignant TFF1-positive MCF7 and ZR75.1. The expression of TFF1 stimulated the migration and invasion in the four cell lines. Forced TFF1 expression in MCF10A, MDA-MB-231 and MCF7 cells did not modify anchorage-dependent or -independent cell proliferation. By contrast, TFF1 knockdown in MCF7 enhanced soft-agar colony formation. This increased oncogenic potential of MCF7 cells in the absence of TFF1 was confirmed in vivo in nude mice. Moreover, chemically induced tumorigenesis in TFF1-deficient (TFF1-KO) mice led to higher tumor incidence in the mammary gland and larger tumor size compared with wild-type mice. Similarly, tumor development was increased in the TFF1-KO ovary and lung. Collectively, our results clearly show that TFF1 does not exhibit oncogenic properties, but rather reduces tumor development. This beneficial function of TFF1 is in agreement with many clinical studies reporting a better outcome for patients with TFF1-positive breast primary tumors.

14 July 2008 in Oncogene
Verified
Journal Article
Closed access
PDF file
EME R Motrescu
E R Motrescu
Sébastien BlaiseSébastien Blaise
Sébastien Blaise
NENicolas ETIQUE
Nicolas ETIQUE
NMN Messaddeq
N Messaddeq
MCM-P Chenard
M-P Chenard
MRM-C Rio
M-C Rio

10 July 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
NENicolas ETIQUE
Nicolas ETIQUE
LVLaurie Verzeaux
Laurie Verzeaux
Stephane DedieuStephane Dedieu
Stephane Dedieu
HEHervé Emonard
Hervé Emonard
Low-density lipoprotein receptor-related protein-(LRP-1) is a large endocytic receptor that binds more than 35 ligands and exhibits signaling properties. Proteinases capable of degrading extracellular matrix (ECM), called matrix proteinases in this paper, are mainly serine proteinases: the activators of plasminogen into plasmin, tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, and the members of the matrix metalloproteinase (MMP) family. LRP-1 is responsible for clearing matrix proteinases, complexed or not with inhibitors. This paper attempts to summarize some aspects on the cellular and molecular bases of endocytic and signaling functions of LRP-1 that modulate extra- and pericellular levels of matrix proteinases.

30 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JTJessica Thevenard
Jessica Thevenard
LVLaurie Verzeaux
Laurie Verzeaux
Jerome DevyJerome Devy
Jerome Devy
NENicolas ETIQUE
Nicolas ETIQUE
AJAlbin Jeanne
Albin Jeanne
HEHervé Emonard
Hervé Emonard
Tissue inhibitor of metalloproteinases-1 (TIMP-1) regulates the extracellular matrix turnover by inhibiting the proteolytic activity of matrix metalloproteinases (MMPs). TIMP-1 also displays MMP-independent activities that influence the behavior of various cell types including neuronal plasticity, but the underlying molecular mechanisms remain mostly unknown. The trans-membrane receptor low-density lipoprotein receptor-related protein-1 (LRP-1) consists of a large extracellular chain with distinct ligand-binding domains that interact with numerous ligands including TIMP-2 and TIMP-3 and a short transmembrane chain with intracellular motifs that allow endocytosis and confer signaling properties to LRP-1. We addressed TIMP-1 interaction with recombinant ligand-binding domains of LRP-1 expressed by CHO cells for endocytosis study, or linked onto sensor chips for surface plasmon resonance analysis. Primary cortical neurons bound and internalized endogenous TIMP-1 through a mechanism mediated by LRP-1. This resulted in inhibition of neurite outgrowth and increased growth cone volume. Using a mutated inactive TIMP-1 variant we showed that TIMP-1 effect on neurone morphology was independent of its MMP inhibitory activity. We conclude that TIMP-1 is a new ligand of LRP-1 and we highlight a new example of its MMP-independent, cytokine-like functions.

9 October 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
OCOcéane Campion
Océane Campion
JTJessica Thevenard-devy
Jessica Thevenard-devy
CBClotilde Billottet
Clotilde Billottet
CSChristophe Schneider
Christophe Schneider
NENicolas ETIQUE
Nicolas ETIQUE
Jerome DevyJerome Devy
Jerome Devy
Background: LRP-1 is a multifunctional scavenger receptor belonging to the LDLR family. Due to its capacity to control pericellular levels of various growth factors and proteases, LRP-1 plays a crucial role in membrane proteome dynamics, which appears decisive for tumor progression. Methods: LRP-1 involvement in a TNBC model was assessed using an RNA interference strategy in MDA-MB-231 cells. In vivo, tumorigenic and angiogenic effects of LRP-1-repressed cells were evaluated using an orthotopic xenograft model and two angiogenic assays (Matrigel® plugs, CAM). DCE-MRI, FMT, and IHC were used to complete a tumor longitudinal follow-up and obtain morphological and functional vascular information. In vitro, HUVECs’ angiogenic potential was evaluated using a tumor secretome, subjected to a proteomic analysis to highlight LRP-1-dependant signaling pathways. Results: LRP-1 repression in MDA-MB-231 tumors led to a 60% growth delay because of, inter alia, morphological and functional vascular differences, confirmed by angiogenic models. In vitro, the LRP-1-repressed cells secretome restrained HUVECs’ angiogenic capabilities. A proteomics analysis revealed that LRP-1 supports tumor growth and angiogenesis by regulating TGF-β signaling and plasminogen/plasmin system. Conclusions: LRP-1, by its wide spectrum of interactions, emerges as an important matricellular player in the control of cancer-signaling events such as angiogenesis, by supporting tumor vascular morphology and functionality.

1 March 2006 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
NENicolas ETIQUE
Nicolas ETIQUE
IGIsabelle Grillier-Vuissoz
Isabelle Grillier-Vuissoz
SFStephane Flament
Stephane Flament
Alcohol consumption is a well-established risk factor for hormone-dependent breast cancer. In vitro studies performed to understand the mechanisms by which ethanol acts on breast cancer cells have shown that this compound stimulates both proliferation and migration. In the present study, we show by gelatin zymography that, when exposed to ethanol, MCF-7 human breast cancer cells display a higher amount of active metalloproteinases (MMP) 2 and 9 in their culture medium. This increase is somewhat higher than those observed in the case of 17beta-estradiol (E2) exposure. As expected, anti-estrogen ICI 182,780 inhibits the E2-induced overexpression of a well-known estrogen responsive gene, the progesterone receptor, in MCF-7 cells. ICI 182,780 also inhibits the E2-induced increase in MMP-2 and -9 secretion. Nevertheless, in the case of ethanol exposure, this ER ant-agonist was only efficient on MMP-9 secretion. In addition, although MMP-9 transcription was not sensitive to E2 or ethanol, MMP-2 transcription was stimulated in MCF-7 cells exposed to ethanol. Collectively, these results give new insights into the effects of alcohol on breast cancer cell migration, which are not due solely to an estrogen-like activity of alcohol.